🇪🇺#NVO #отчетность Novo Nordisk Q3 Earnings: - Adj Sales: DKK79.20B (est DKK73.55B) - Adj Net: DKK25.60B (est DKK21.47B) - Sees FY Adjusted Sales At CER: -2% To +2% (est -2.35%) - Sees FY Adjusted Operating Profit At CER: -2% To +2% - Ozempic Sales: DKK29.71B (est DKK27.19B) Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%